Patents by Inventor John Gillard

John Gillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR DIFFERENTIATING BETWEEN MULTIPLE SCLEROSIS SUBTYPES
    Publication number: 20110136133
    Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 9, 2011
    Applicant: Dianovix, Inc.
    Inventors: Virender BHAN, John Gillard, Andrea Hebb, Martin Holcik, Robert G. Korneluk, George Robertson
  • IAP BIR DOMAIN BINDING COMPOUNDS
    Publication number: 20100203012
    Abstract: Disclosed herein is a compound of Formula 1: or a salt thereof, in which R1, R1a, R100, R100a, R2, R200, R3, R300, A, A1, Q, Q1 and BG are as defined herein. Also disclosed is the use of the compounds of Formula 1 to treat disorders of dysregulated apoptosis, such as cancer and cellular proliferative disorders.
    Type: Application
    Filed: May 30, 2008
    Publication date: August 12, 2010
    Applicant: Aegera Therapeutics, Inc.
    Inventors: Alain Laurent, Patrick Bureau, James Jaquith, John Gillard, Yannick Rose
  • Comprehensive Theft Security System
    Publication number: 20080309491
    Abstract: An antitheft security system and method using networked pedestals for monitoring, and reporting data relating to, merchandise, having security tags coupled to or embedded therein, leaving or entering a business establishment and alerting business establishment personnel when a theft may be occurring. The system and method collect and communicate security tag data and associated peripheral device data to a remote server for analysis.
    Type: Application
    Filed: June 5, 2008
    Publication date: December 18, 2008
    Applicant: Checkpoint Systems, Inc.
    Inventors: John Gillard, David Ivins, Nathaniel Lacsamana, Harry Oung, Nimesh Shah, Bogdan Sima
  • Method of treating autoimmune diseases
    Publication number: 20080293653
    Abstract: The invention features a method of inducing an apoptosis-resistant cell to undergo apoptosis, in which the cell is associated with an autoimmune disease such as multiple sclerosis. The method involves sensitizing the cell to apoptosis stimuli by treating the cell with an IAP antisense oligonucleotide, so that the cell undergoes apoptosis at a site of autoimmune disease.
    Type: Application
    Filed: October 12, 2005
    Publication date: November 27, 2008
    Inventors: Jon Durkin, John Gillard, Trevor Owens, Stephen Morris, Simone Patricia Zehnter
  • Method for differentiating between multiple sclerosis subtypes
    Publication number: 20080020388
    Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
    Type: Application
    Filed: February 6, 2007
    Publication date: January 24, 2008
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventors: Virender Bhan, John Gillard, Andrea Hebb, Martin Holcik, Robert Korneluk, George Robertson
  • Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides
    Publication number: 20070265319
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Application
    Filed: May 7, 2007
    Publication date: November 15, 2007
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventors: James Jaquith, Alain Boudreault, Stephen Morris, Jon Durkin, John Gillard, Kimberley Hewitt
  • Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides
    Publication number: 20070238768
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Application
    Filed: May 7, 2007
    Publication date: October 11, 2007
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventors: James Jaquith, Alain Boudreault, Stephen Morris, Jon Durkin, John Gillard, Kimberley Hewitt
  • Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof
    Publication number: 20070112043
    Abstract: This invention relates to novel compounds of Formula (I): and the use of compounds of Formula (I) in the treatment of neuronal disorders of the central and peripheral nervous systems and for the treatment of proliferative diseases, such as cancer.
    Type: Application
    Filed: June 14, 2004
    Publication date: May 17, 2007
    Inventors: James Jaquith, John Gillard
  • Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides
    Publication number: 20070088059
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Application
    Filed: April 6, 2006
    Publication date: April 19, 2007
    Inventors: James Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen Morris, Jon Durkin, John Gillard, Kimberley Hewitt, H. Marsh
  • Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides
    Publication number: 20070021416
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Application
    Filed: April 6, 2006
    Publication date: January 25, 2007
    Inventors: James Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen Morris, Jon Durkin, John Gillard, Kimberley Hewitt, H. Marsh
  • Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides
    Publication number: 20070021476
    Abstract: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Application
    Filed: April 5, 2006
    Publication date: January 25, 2007
    Inventors: James Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen Morris, Jon Durkin, John Gillard, Kimberley Hewitt, H. Marsh
  • Neuroprotective and anti-proliferative compounds
    Publication number: 20060199835
    Abstract: This invention features compounds of formula (I), (II) and (III), which are useful in the treatment of proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation. Formulas (I), (II), (III) have functional groups designated as A1, A2, B1, B2, X1—X9 and R1—R8 as defined further.
    Type: Application
    Filed: August 11, 2004
    Publication date: September 7, 2006
    Inventors: James Jaquith, John Gillard, Alain Laurent
  • Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones
    Publication number: 20060135571
    Abstract: This invention relates to novel imidazo[2,1-b]-1,3,4-thiadiazole sulfoxide and sulfone compounds of Formula (I) and the use of compounds of Formula (I) in the treatment of neuronal disorders of the central and peripheral nervous systems and for the treatment of proliferative diseases such as cancer.
    Type: Application
    Filed: June 14, 2004
    Publication date: June 22, 2006
    Inventors: James Jaquith, John Gillard, Patrick Bureau, Scott Jarvis
  • Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
    Publication number: 20050069492
    Abstract: This invention relates to compounds of Formula (I) and the use of compounds of Formula (I) as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
    Type: Application
    Filed: December 16, 2002
    Publication date: March 31, 2005
    Inventors: James Jaquith, Gerald Villeneuve, Alain Boudreault, Stephen Morris, Jon Durkin, John Gillard, Kimberly Hewitt, H. Marsh
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5380850
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: January 10, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, Richard Frenette, John Gillard
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5272145
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: December 21, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, Richard Frenette, John Gillard
  • (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
    Patent number: 5204344
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.
    Type: Grant
    Filed: February 5, 1991
    Date of Patent: April 20, 1993
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Rejean Fortin, John H. Hutchinson, Michel L. Belley, Serge Leger, John Gillard, Richard Frenette
  • Leukotriene antagonists
    Patent number: 4871756
    Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4, E.sub.4 and the slow reacting substance of anaphylaxis.As such, these compounds will be useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: February 17, 1987
    Date of Patent: October 3, 1989
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John Gillard, Joshua Rokach, Patrice C. Belanger
  • Leukotriene antagonists
    Patent number: 4667055
    Abstract: Compounds having the formula: ##STR1## are antagonists of leukotrienes of C.sub.4, D.sub.4 E.sub.4 and the slow reacting substance of anaphylaxis.As such, these compounds will be useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: March 20, 1985
    Date of Patent: May 19, 1987
    Assignee: Merck Frosst Canada, Inc.
    Inventors: John Gillard, Joshua Rokach, Patrice C. Belanger